Beta Bionics, Inc. Common Stock BBNX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $27.63M-14.0% | $32.12M+17.9% | $27.25M+17.3% | $23.24M+31.7% | $17.64M-13.7% | ||
| $11.19M-15.1% | $13.18M+8.6% | $12.13M+13.0% | $10.74M+23.8% | $8.67M-0.9% | ||
| $16.44M-13.2% | $18.94M+25.3% | $15.12M+20.9% | $12.5M+39.4% | $8.97M-23.3% | ||
| 59.5%+0.5pp | 59%+3.5pp | 55.5%+1.7pp | 53.8%+2.9pp | 50.9%-6.3pp | ||
| $10.36M+2.2% | $10.13M+23.6% | $8.2M-7.6% | $8.87M+16.9% | $7.59M-17.6% | ||
| $20.74M+26.9% | $16.33M+1.8% | $16.05M+2.7% | $15.62M+16.6% | $13.4M+24.0% | ||
| $9.62M+11.8% | $8.6M+8.6% | $7.92M+0.5% | $7.88M+19.0% | $6.62M+40.6% | ||
| $40.71M+16.1% | $35.07M+9.0% | $32.16M-0.7% | $32.38M+17.2% | $27.61M+11.7% | ||
| $40.71M+16.1% | $35.07M+9.0% | $32.16M-0.7% | $32.38M+17.2% | $27.61M+11.7% | ||
| -$24.27M-50.5% | -$16.12M+5.4% | -$17.04M+14.2% | -$19.87M-6.6% | -$18.64M-43.0% | ||
| -87.9%-37.7pp | -50.2%+12.3pp | -62.5%+23.0pp | -85.5%+20.2pp | -105.7%-41.9pp | ||
| $2.38M-10.6% | $2.66M-6.2% | $2.83M-5.7% | $3.01M+23.4% | $2.44M+156% | ||
| $2.38M— | —— | $2.83M-5.6% | $3M+130% | -$10.01M-97.5% | ||
| -$21.9M-62.6% | -$13.47M+5.2% | -$14.21M+15.8% | -$16.87M+41.1% | -$28.66M-58.3% | ||
| -79.3%-37.3pp | -41.9%+10.2pp | -52.1%+20.5pp | -72.6%+89.9pp | -162.5%-73.9pp | ||
| -$0.49-69.0% | -$0.29+12.1% | -$0.33+15.4% | -$0.39+58.1% | -$0.93+66.1% | ||
| -$0.49-69.0% | -$0.29+12.1% | -$0.33+15.4% | -$0.39+58.1% | -$0.93+66.1% | ||
| 44.4M+9.6% | 40.5M-7.1% | 43.6M+0.6% | 43.4M+41.3% | 30.7M+383% | ||
| 44.4M+9.6% | 40.5M-7.1% | 43.6M+0.6% | 43.4M+41.3% | 30.7M+383% | ||
| -$22.39M-66.9% | -$13.42M+4.2% | -$14M+17.4% | -$16.96M+40.5% | -$28.48M-57.3% | ||
| -$499K-1,118% | $49K-76.1% | $205K+325% | -$91K-152% | $175K— | ||
| $27.63M-14.0% | $32.12M+17.9% | $27.25M+17.3% | $23.24M+31.7% | $17.64M-13.7% | ||
| -$24.27M-50.5% | -$16.12M+5.4% | -$17.04M+14.2% | -$19.87M-6.6% | -$18.64M-43.0% | ||
| -$23.69M-52.0% | -$15.59M+6.4% | -$16.66M+14.7% | -$19.53M-6.5% | -$18.34M-43.2% | ||
| -$23.69M-52.0% | -$15.59M+6.4% | -$16.66M+14.7% | -$19.53M-6.5% | -$18.34M-43.2% | ||
| -85.7%-37.2pp | -48.5%+12.6pp | -61.1%+22.9pp | -84%+19.9pp | -104%-41.3pp | ||
| -$24.27M-50.5% | -$16.12M+5.4% | -$17.04M+14.2% | -$19.87M-6.6% | -$18.64M-43.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Beta Bionics, Inc. Common Stock's revenue?
- Beta Bionics, Inc. Common Stock (BBNX) generated $110.2M in revenue over the trailing twelve months, up 57.9% year over year.
- Is Beta Bionics, Inc. Common Stock profitable?
- Beta Bionics, Inc. Common Stock is not currently profitable: it reported a net loss of $66.4M over the trailing twelve months, a -60.3% net margin.
- What are Beta Bionics, Inc. Common Stock's profit margins?
- Gross margin is 57.2% and operating margin is -70.1%, with a -60.3% net margin.
- What is Beta Bionics, Inc. Common Stock's earnings per share?
- Beta Bionics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.50.
- Where does Beta Bionics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Beta Bionics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
